Atricure Stock Price, News & Analysis

AtriCure, a leader in surgical treatments for atrial fibrillation (Afib), will present at the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022, at 8:40 a.m. Eastern Time. Interested parties can access the live audio webcast via the company's website. AtriCure offers innovative solutions for Afib, impacting over 33 million people globally. Their FDA-approved Isolator® Synergy™ Ablation System is a key technology, along with the widely used AtriClip® for left atrial appendage management.

AtriCure, a leader in surgical treatments for atrial fibrillation, announced it will release its fourth quarter and full year 2021 financial results on February 15, 2022. A conference call will follow at 4:30 p.m. ET the same day, accessible via phone or live audio webcast. AtriCure offers innovative technologies including the Isolator® Synergy™ Ablation System and AtriClip® products, which are widely used for managing Afib. With over 33 million people affected by Afib globally, AtriCure is committed to improving patient outcomes.

AtriCure, Inc. (NASDAQ: ATRC) reported preliminary financial results for Q4 and full year 2021, showing approximately $73.2 million in Q4 revenue, a 27% increase from 2020. Full-year revenue for 2021 is projected at $274.3 million, reflecting a 33% year-over-year growth. However, adjusted EBITDA showed a loss of $10 million, with an estimated loss per share of $1.20. Looking ahead, AtriCure projects 2022 revenue between $315 million and $330 million, indicating a 15-20% growth outlook amidst ongoing COVID-19 uncertainties.

AtriCure, Inc. (NASDAQ: ATRC), a leader in surgical treatments for atrial fibrillation (Afib), will participate in the 40th Annual J.P. Morgan Healthcare Conference. Management's presentation is scheduled for January 10, 2022, at 7:30 a.m. ET. Investors can access the live audio webcast through the company’s website. AtriCure specializes in innovative technologies for Afib management, including the FDA-approved Isolator® Synergy™ Ablation System, and widely used AtriClip® devices for left atrial appendage management. For more details, visit AtriCure.com.

AtriCure, a leader in surgical treatments for atrial fibrillation (Afib), announced its participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference. A prerecorded fireside chat is scheduled for November 22, 2021, accessible via the company's website. Additionally, management will hold investor meetings on December 1, 2021. AtriCure focuses on innovative technologies for Afib management, impacting over 33 million people globally, with notable products including the Isolator® Synergy™ Ablation System and AtriClip® Left Atrial Appendage Exclusion System.

AtriCure, a leader in atrial fibrillation treatments, reported strong Q3 2021 results with revenues of $70.5 million, a 28.7% increase year-over-year. U.S. revenue rose to $57.5 million due to stable cardiac procedures and high demand for Cryo Nerve Block and Hybrid AF therapy products. However, worldwide revenue fell by 1.3% from Q2 2021. Gross profit reached $52.2 million, with a gross margin of 74.1%. The company maintains its 2021 revenue guidance of $270-$275 million and adjusted EBITDA loss of approximately $10 million.

AtriCure, Inc. (NASDAQ: ATRC) announces participation in upcoming investor conferences, presenting at the Stifel 2021 Virtual Healthcare Conference on November 17, 2021, at 8:40 a.m. Eastern Time. A live audio webcast will be available on the company's website. Additionally, AtriCure will host investor meetings at the Canaccord Genuity Virtual MedTech Forum on November 18, 2021. AtriCure focuses on innovative surgical solutions for atrial fibrillation and left atrial appendage management, with devices like the FDA-approved Isolator® Synergy™ Ablation System.

AtriCure, a leader in atrial fibrillation (Afib) treatments, has announced the release of its third quarter 2021 financial results on November 3, 2021. A conference call will take place at 4:30 p.m. ET to discuss these results, which can be accessed via phone or through a live audio webcast. AtriCure's technologies, including the Isolator® Synergy™ Ablation System and AtriClip® products, are critical in treating over 33 million people affected by Afib globally. These innovations position AtriCure as a prominent player in the medical device market.

AtriCure, Inc. (NASDAQ: ATRC), a leader in surgical treatments for atrial fibrillation (Afib), announced its participation in the Morgan Stanley 19th Annual Global Healthcare Conference. The presentation is set for Tuesday, September 14, 2021, at 11:45 a.m. Eastern Time. Attendees can access a live or archived audio webcast via the Investors section of AtriCure's website. AtriCure innovates treatments for Afib, impacting over 33 million people worldwide, and offers products like the Isolator® Synergy™ Ablation System and AtriClip® LAA management devices.